Streetbeat News

Price Targets

AMP

Goldman Sachs analyst Alexander Blostein has upgraded Ameriprise Financial (NYSE:AMP) from Neutral to Buy and set a price target of $452.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 9:41 am

ARQT

Mizuho analyst Uy Ear has upgraded Arcutis Biotherapeutics (NASDAQ:ARQT) from Neutral to Buy and increased the price target from $4 to $8, indicating a more positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 9:39 am

ENV

Raymond James analyst Patrick O'Shaughnessy has maintained an Outperform rating on Envestnet (NYSE:ENV) and increased the price target from $46 to $55.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 9:31 am

TRBUSD

Tellor (TRB), a decentralized Oracle protocol, experienced a significant price drop of 13.8% in the past 24 hours after reaching an all-time high on Jan. 1, 2024. The team deposited 4,211.7 TRB worth $2.4 million post the price surge. Whales have been accumulating TRB, with wealthy traders adding 15% of the total supply to their holdings in the last seven days. On-chain data suggests that 26% of TRB's circulating supply is held by just 20 wallets, raising concerns of potential manipulation and a pump-and-dump cycle. The price action over the past month shows TRB is up by 109.3%, despite the recent drop and a narrowed trading volume by 81.9%.

Portfolio Pulse from Khyathi Dalal

January 02, 2024 | 10:39 pm

ARQT

Mizuho analyst Uy Ear has upgraded Arcutis Biotherapeutics (NASDAQ:ARQT) from Neutral to Buy and increased the price target from $4 to $8, indicating a more positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 9:19 pm

FWBI

First Wave BioPharma's stock price has increased following an updated price target from Roth MKM, which raised its PT to $40.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 9:15 pm

CFLT

MDB

Needham analyst Mike Cikos maintained a Buy rating on Confluent Inc (CFLT) and raised the price target from $23 to $30, adding it to Needham's Conviction List for 2024 as the top Infrastructure and Analytics Software pick, replacing MongoDB, Inc (MDB). CFLT is seen as undervalued after a recent run-up and is expected to have multiple growth vectors in CY24. The company's go-to-market transformation and product roadmap, including Flink's general availability and potential FedRAMP authorization, are seen as catalysts. The management's CY24 outlook accounts for multiple headwinds, with Q4 revenue and EPS projections aligning with consensus estimates. CFLT shares closed lower by 2.91% at $22.72.

Portfolio Pulse from Anusuya Lahiri

January 02, 2024 | 9:12 pm

XHR

Analysts have recently updated their ratings and price targets for Xenia Hotels & Resorts (NYSE:XHR), with a mix of opinions ranging from bullish to bearish. Over the last three months, there have been changes in sentiment, with the current average 12-month price target set at $13.5, up from the previous $13.25. Analysts from Jefferies, Wells Fargo, Keybanc, and Morgan Stanley have adjusted their ratings and price targets, reflecting their views on the company's market dynamics and performance. Xenia Hotels & Resorts is a REIT focusing on upscale hotels in the U.S., but it faces challenges with revenue decline, below-average net margin, ROE, and ROA, although it has a healthier debt-to-equity ratio compared to the industry.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 9:01 pm

WLK

Westlake (NYSE:WLK) received mixed analyst ratings over the past three months, with no change in the last 30 days. The average 12-month price target is $140.5, slightly down from $140.75. UBS, Piper Sandler, and B of A Securities have adjusted their price targets and ratings, reflecting their latest views on the company's performance. Westlake's financials show a negative revenue trend with a -21.26% growth, but strong profitability with a net margin of 9.09% and above-average ROE and ROA. The company has a lower than industry average debt-to-equity ratio of 0.5.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 9:01 pm

SMTC

In the last three months, 6 analysts have provided diverse ratings for Semtech (NASDAQ:SMTC), with a shift towards a more bearish sentiment. The average 12-month price target has been reduced by 9.24%, with a current average of $28.5. Analysts from firms like Stifel, Roth MKM, Needham, Susquehanna, and Benchmark have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Semtech's financials show a positive revenue trend but challenges in net margin, ROE, ROA, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 9:01 pm